编辑信息

Trinseo Targets Medical Sector with Biocompatible Glass-Filled Polycarbonate

CALIBRE™ 5000 Series supports growth in minimally-invasive surgeries and industry cost reduction

BERWYN, Pa. - Wednesday, October 31, 2018

Trinseo  (NYSE: TSE) a global materials solutions provider and manufacturer of plastics, latex binders and synthetic rubber, is targeting the medical devices market with its biocompatible glass-filled polycarbonate resins. Trinseo’s CALIBRE 5000 series is an ideal material for metal substitution not only because of its strength and stiffness, but its added advantages of aesthetics, ergonomic improvements, and potential cost savings.

“As minimally-invasive surgeries increase and cost pressures continue to mount, Trinseo’s glass-filled polycarbonate is ideal for a variety of surgical tools and surgery access instruments,” said Arthas Yang, global marketing manager in Trinseo’s Performance Plastics business. “The material can be incorporated into a variety of applications, according to design and regulatory requirements, and can help manufacturers with their goals of lowering cost and increasing speed-to-market.”

Glass-filled materials have been used in numerous application areas for years. What differentiates Trinseo’s CALIBRE™ 5000 series is the fact that it has undergone extensive biocompatibility testing according to ISO 10993 standards to provide medical device manufacturers with added assurance of compliancy and patient safety.  

The CALIBRE™ 5000 series offers the following:

  • Custom glass content of up to 30 percent
  • Full battery of ISO 10993 biocompatibility testing
  • UL flammability ratings
  • Sterilizable  by EtO, gamma, and e-beam radiation

From an aesthetic perspective the material can be colored for branding and parts-identification purposes. Due to its processability and the design flexibility it allows, parts can be consolidated for cost savings and simplified assembly, reducing the number of seams and crevasses where bacteria can grow.  

Trinseo has supported the medical devices market for three decades.  The company offers a variety of plastics under the brands CALIBRE™ and CALIBRE™ MEGARAD™ Polycarbonate Resins, EMERGE™ Advanced Resins, MAGNUM™ ABS  Resins, and STYRON™ Polystyrene Resins.  Thermoplastic elastomers offered by Trinseo for soft-touch medical applications are MEGOL™ MED TPS-SEBS Compounds and RAPLAN™ MED TPS-SBS Compounds.

About Trinseo

Trinseo (NYSE:TSE) is a global materials solutions provider and manufacturer of plastics, latex binders, and synthetic rubber with a focus on delivering innovative, sustainable, and value-creating products that are intrinsic to our daily lives. Trinseo is dedicated to making a positive impact on society by partnering with like-minded stakeholders, and supporting the sustainability goals of our customers in a wide range of end-markets including automotive, consumer electronics, appliances, medical devices, packaging, footwear, carpet, paper and board, building and construction, and tires. Trinseo had approximately $3.0 billion in net sales in 2020, with 17 manufacturing sites around the world, and approximately 2,600 employees. For more information, please visit: www.trinseo.com.

Cautionary Note on Forward-Looking Statements

This press release may contain forward-looking statements including, without limitation, statements concerning plans, objectives, goals, projections, strategies, future events or performance, and underlying assumptions and other statements, which are not statements of historical facts or guarantees or assurances of future performance. Forward-looking statements may be identified by the use of words like "expect," "anticipate," "intend," "forecast," "outlook," "will," "may," "might," "see," "tend," "assume," "potential," "likely," "target," "plan," "contemplate," "seek," "attempt," "should," "could," "would" or expressions of similar meaning. Forward-looking statements reflect management’s evaluation of information currently available and are based on our current expectations and assumptions regarding the timing of the proposed acquisition of the Arkema MMA and PMMA business (the "Acquisition"); estimated and future results of operations, business strategies, competitive position, industry environment and potential growth opportunities and cost synergies relating to the Acquisition, our business, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Factors that might cause such a difference include, but are not limited to, our failure to complete the Acquisition or meet the conditions to closing, including antitrust, works council and other regulatory approvals; the failure to obtain the financing necessary to fund the Acquisition and the impact of the substantial indebtedness to be incurred; costs related to the Acquisition; following the Acquisition, our ability to successfully integrate the acquired businesses, generate expected cost savings and synergies, maintain relationships with customers, retain key employees and profitably grow the business; and those factors discussed in our Annual Report on Form 10-K, under Part I, Item 1A —"Risk Factors" and elsewhere in our other reports, filings and furnishings made with the U.S. Securities and Exchange Commission from time to time. As a result of these or other factors, our actual results may differ materially from those contemplated by the forward-looking statements. Therefore, we caution you against relying on any of these forward-looking statements. The forward-looking statements included in this press release are made only as of the date hereof. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law.

编辑信息

接收盛禧奥独家内容

方便地通过电子邮件抢先了解新产品信息、公司新闻及其它盛禧奥资讯动态!